Bridgefront Capital, LLC Akero Therapeutics, Inc. Transaction History
Bridgefront Capital, LLC
- $331 Million
- Q1 2025
A detailed history of Bridgefront Capital, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 10,736 shares of AKRO stock, worth $422,139. This represents 0.13% of its overall portfolio holdings.
Number of Shares
10,736Holding current value
$422,139% of portfolio
0.13%Shares
3 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
85.9MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$292 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$278 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$233 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$220 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$206 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.83B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...